Research Article

Bioinformatics Analysis for Constructing a Six-Immune-Related Long Noncoding RNA Signature as a Prognostic Model of Hepatocellular Carcinoma

Jue Wang, Zongrui Jin, Guolin Wu, Jilong Wang, Banghao Xu, Hai Zhu, Ya Guo, and Zhang Wen

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021 Guangxi Province, China

Correspondence should be addressed to Zhang Wen; wenzgxmu@126.com

Received 1 April 2022; Accepted 21 June 2022; Published 7 July 2022

Academic Editor: Surendiran B

Copyright © 2022 Jue Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The present study was aimed at identifying the potential prognostic biomarkers of the immune-related long noncoding RNA (IRL) signature for patients with hepatocellular carcinoma (HCC). RNA-sequencing data and clinical information about HCC were obtained from The Cancer Genome Atlas. The IRLs were determined with regard to the coexpression of immune-related genes and differentially expressed lncRNAs. The survival IRLs were obtained using the univariate Cox analysis. Subsequently, the prognosis model was constructed via the multivariate Cox analysis. Subsequently, functional annotation was conducted using Gene Set Enrichment Analysis (GSEA) and principal component analysis (PCA). In total, 341 IRLs were identified, and 6 IRLs were found to have a highly significant association with the prognosis of patients with HCC. The immune prognosis model was constructed with these 6 IRLs (AC099850.4, negative regulator of antiviral response, AL031985.3, PRRT3-antisense RNA1, AL365203.2, and long intergenic nonprotein coding RNA 1224) using the multivariate Cox regression analysis. In addition, immune-related prognosis signatures were confirmed as an independent prognostic factor. The association between prognostic signatures and immune infiltration indicated that the 6 lncRNAs could reflect the immune status of the tumor. Collectively, the present study demonstrates that six-lncRNA signatures may be potential biomarkers to predict the prognosis of patients with HCC.

1. Introduction

Liver cancer is a common type of malignant tumor, ranking third for all tumor mortality, accounting for >700,000 deaths and 800,000 new cases each year worldwide [1]. HCC accounts for 75-85% of all primary liver cancer types and is the most common primary malignant tumor. Common risk factors for HCC include hepatitis B virus, hepatitis C virus, chronic drinking, and aflatoxin, amongst others [2]. As the early symptoms of HCC are not obvious, the majority of patients are at the middle and late stages of clinical diagnosis and, as a result, lose the opportunity for surgical treatment [3]. Although chemotherapy and interventional therapy can be used, the survival rate of patients remains low [4]. Currently, surgery is the most effective treatment method for early HCC [5]. It has been reported that sorafenib and lenvatinib have an excellent curative effect for advanced HCC [6, 7]. Due to the high mortality of HCC, it is a necessity to identify valuable targets for promoting the diagnosis, treatment, and prognosis of HCC.

Recent research has suggested that the immune microenvironment has a critical effect on the pathogenesis of HCC [8]. As a typical inflammatory tumor type, immune tolerance and immune escape significantly affect the development of HCC [9]. For instance, myeloid-derived suppressor cells promote tumor development by enhancing the expression levels of immunosuppressive factors [10, 11]. Therefore, further studies are required to determine how to identify immune-related factors.
Long noncoding RNAs (lncRNA) are a class of untranslated RNA molecules, usually >200 nucleotides in length, that do not encode proteins. Gene regulation mediated by lncRNAs can regulate the expression levels of inflammatory genes in innate immune cells [12]. Previous studies have reported that the abnormal expression of lncRNA is actively involved in tumorigenesis and metastasis [13, 14]. In addition, multiple lncRNAs promote the immune escape of tumor cells [15]. For instance, lnc-EGFR stimulates regulation, multiple lncRNAs promote the immune escape of HCC. Furthermore, urothelial cancer associated 1 performs a similar function in gastric cancer cells [16]. Nevertheless, the main mechanism of IRLs in the prediction of HCC remains unknown.

In our research, according to TCGA RNA-sequencing (seq) data, IRLs associated with HCC prognosis were identified using the Molecular Signatures Database (MSigDB), and a prognostic model of HCC was established. The current aim was to use the expression profile of lncRNAs to identify IRLs, which could help to identify a potential prognostic indicator of HCC and a promising target for immunotherapy.

2. Material and Methods

2.1. Dataset Source and Sample Collection. RNA-seq data for 371 patients with HCC were obtained from TCGA (https://portal.gdc.cancer.gov/) [17]. Data collection was needed to meet the following requirements: the pathological type of all patients was HCC in the dataset; the data included a complete lncRNA expression profile; the data included detailed clinical information and overall survival time, such as sex, age, pathological grade, pathological stage, and TNM stage (Table S1). Samples without complete clinical information and an overall survival (OS) of ≤90 days were excluded. RNA-seq data were HTSeq-FPKM type, not requiring further standardization. Genes with averaged expression values close to zero were deleted. If there are multiple identical genes, the average expression value will be taken as the expression level of the gene. In total, six clinical samples of HCC and paracancerous samples were collected from patients (Table S2). The collected tissues were instantly frozen in liquid nitrogen and stored in a -80°C refrigerator. The study has obtained the patients’ informed consent and been approved by the ethics committee of the First Affiliated Hospital of Guangxi Medical University. The research was conducted in accordance with the Declaration of Helsinki.

2.2. Screening of Differentially Expressed Immune-Related lncRNAs. Immune-associated genes were acquired from the MSigDB v7.0 (immune system process M13664 and immune response M19817, https://www.gsea-msigdb.org/gsea/index.jsp) [18, 19]. In addition, the lncRNA expression data were obtained from TCGA RNA-seq data and the GENCODE database (https://www.gencodegenes.org/) [20]. lncRNAs with an average value of >0.2 were included in the differentially expressed lncRNA (DElncRNA) screening. DElncRNAs were obtained via the Wilcoxon test method in the R package of limma (|log 2FC| > 1 and false discovery rate (FDR) < 0.05, version 3.42.2, https://bioconductor.org/packages/release/bioc/html/limma.html). Then, IRLs were obtained by establishing the coexpression network of immune genes and lncRNAs (|R| > 0.5; P < 0.001) using the cor.test function [21] in R.

2.3. Cox Regression. lncRNAs related to prognosis were identified via the univariate Cox regression, using the survival package of R (P < 0.001). The survival package was used to calculate the risk score via stepwise regression multivariate Cox analysis [22, 23]. The formula used was as follows: Risk score= β_I_{lncRNA}_1 × expression level of lncRNA1 + β_I_{lncRNA}_2 × expression level of lncRNA2 + ···+ β_I_{lncRNA_n} × expression level of lncRNA_n. The median risk score divided the 329 samples into low- and high-risk groups. The Kaplan-Meier survival curve of patients in the two groups was plotted using the survival and survminer packages of R. Based on the six-lncRNA signatures and clinicopathological features, the independent prognostic factors of HCC were analyzed via the Cox regression analyses. The receiver operating characteristic (ROC) curve was used to estimate the accuracy of prognosis prediction within 5 years. All displayed P values were two-sided.

2.4. Bioinformatics Analysis. Functional annotation was performed between different risk groups via GSEA (http://www.broadinstitute.org/gsea/index.jsp) [24]. The immune system process M13664 and the immune response M19817 (C5) gene sets were downloaded from the GSEA website and MSigDB database. The GSEA version 4.0.3 software was used to analyze the data, and the current study set a random combination of 1,000 analyses. Moreover, PCA was used to evaluate the distribution patterns of various risk groups.

2.5. Correlation Analysis of Prognostic Model and Immune Cell Infiltration. The connection between the prognosis model and immune invasion was calculated via TIMER [25], which is a powerful tool to study tumor immune cell infiltration. TIMER involves the infiltration level of six types of immune cells (B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils, and dendritic cells). The immune infiltration level for patients with HCC was obtained via the TIMER database. In addition, the relationship between prognosis signatures and immune infiltration was analyzed with R 3.6.0.

2.6. Reverse Transcription-Quantitative (RT-q) PCR. According to the reagent instructions, the total RNA was extracted with RNAiso Plus reagent (Takara Bio, Inc.) and then was reverse transcribed into cDNA using PrimeScript™ RT reagent kit with a gDNA Eraser (Takara Bio, Inc.) at 37°C for 15 min and 85°C for 5 sec. The TB Green Premix Ex Taq™ II kit (Takara Bio, Inc.) was used for qPCR in an ABI 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The 20 μl system included 10 μl TB Green Premix Ex Taq II, 0.8 μl each primer, 0.4 μl ROX Reference Dye II, 2 μl cDNA, and 6 μl double distilled water. The thermocycling conditions were as follows: initial denaturation for 30 sec at 95°C, followed by 40 cycles for
Figure 1: Continued.
Figure 1: DElncRNAs and immune-related lncRNAs in hepatocellular carcinoma based on The Cancer Genome Atlas dataset. (a) Heatmap of DElncRNAs. The color from green to red displays the trend from low to high expression. (c) Volcano plot of DElncRNAs. Red dots represent upregulated genes and green dots represent downregulated genes. (b) Heatmap and (d) volcano plot of differential expression of immune-related lncRNAs. Six immune-related lncRNAs constructing the prognostic model were upregulated. lncRNA: long noncoding RNA; DElncRNAs: differentially expressed lncRNAs; FC: fold change; FDR: false discovery rate; NRAV: negative regulator of antiviral response; PRRT3-AS1: PRRT3-antisense RNA1; LINC01224: long intergenic nonprotein coding RNA 1224.
5 sec at 95°C, and 34 sec at 60°C. The primer pairs were as follows: AC099850.4 forward (5′-3′), AGGCTGGAGTG GCAGTTGTT and reverse (5′-3′), GTGAGACCTAGTTC CCTGTTGT; negative regulator of antiviral response (NRAV) forward (5′-3′), CTCTGTTCCCAGCCCAGTC and reverse (5′-3′), CTGGTTGAGACCCACT GTAGA and reverse (5′-3′) CTGGAGCCAAACAGAAA CCTAA; PRRT3-antisense RNA (AS1) forward (5′-3′), GAAATGGGATAAACGGCAGC and reverse (5′-3′), AGCGTGTGACAGTGAGTA; and β-actin forward (5′-3′), CTGGTGGACCTAGTTC and reverse (5′-3′), CTACCT CATGAAGATCCTCACCGA and reverse (5′-3′), CCTAA; PRRT3-antisense RNA1 forward (5′-3′), CTACCT CATGAAGATCCTCACCGA and reverse (5′-3′), TTCTCC TTAATGTCAGCGAGTT.

2.7. Statistical Analysis. In the current research, IRLs were identified via Pearson’s correlation analysis. The difference in OS between various risk groups was evaluated via the Kaplan-Meier curve analysis and the log-rank test. The independent prognostic factors for HCC were determined via the multivariate Cox regression analysis. Di
defendent prognostic risk factors for HCC in the six lncRNAs. Information regarding the six lncRNA signatures is listed in Table 1.

Next, according to the median risk score (Figure 2(a)), 329 liver cancer samples were divided into two groups: the high-risk group (n = 164) and the low-risk group (n = 165). Figures 2(b) and 2(c) showed the survival profile and gene expression heatmap, respectively. The survival curve suggested that, compared with the low-risk group, the overall survival time of the high-risk group decreased markedly (P = 1.54 × 10−7; Figure 2(d)). The area under the ROC curve (AUC) was performed to calculate the prediction performance of the six-lncRNA model. The AUC values of the ROC curve for 1-, 3-, and 5-year OS were 0.797, 0.692, and 0.616, respectively, which indicated that the model had good sensitivity and specificity (Figure 2(e)). In addition, it was found that, compared with a single lncRNA, this signature had an improved overall survival prediction ability (Fig. S2).

3.3. Independence of Risk Score and Clinical Characteristics. Clinical data of 214 patients with HCC, including sex, age, histological grade, pathological stage, and TNM stage, were collected for the following research. The independent predictive capability of the six-lncRNA characteristics was evaluated via the Cox analysis. Univariate analysis identified that pathological stage, T stage, and the six-lncRNA prognosis model were significantly associated with the OS rate (P < 0.001). After the multivariate Cox regression analysis, only the prognosis model of IRLs remained an independent prognostic factor in association with OS (P < 0.001; Table 2).

In addition, the current study analyzed the correlation between the prognosis model and clinical features. Our research demonstrated that the risk score was increased remarkably in relation to the following clinical features: female, advanced T stage, and pathological stage (Fig. S3A–C), which further confirmed the clinical application value of the model. It was also found that the expression levels of AC099850.4, AL031985.3, and NRAV were gradually increased in the advanced T stage (Fig. S3D). Moreover, all six lncRNAs were highly expressed in more advanced histological grades (Fig. S3E), which provided insights for further detection of tumor biomarkers.
Figure 2: Continued.
3.4. Immune Status Analysis for Different Risk Groups. In accordance with the expression profiles of whole genome and immune-associated genes, different expression patterns were identified between different risk groups via PCA. The results demonstrated that, according to the immune gene sets, the two groups could be distinguished and displayed different immune statuses (Figure 3(a)). However, according to the whole gene expression profile, PCA indicated that there was no significant separation in immune status between these groups (Figure 3(b)). GSEA further verified
the functional annotation. In the high-risk group, the immune-associated process and response were more positive (Figures 3(c) and 3(d)). The results suggested that the high-risk group had more immune-related reactions.

In order to clarify the momentousness of the IRLs in the tumor microenvironment, the correlation between the six lncRNA prognostic model and immune infiltration was evaluated. As presented in Figure 4, six types of immune cells were positively correlated with the risk score. Therefore, immune cells may be more active in the high-risk group according to the prognostic signature.

3.5. Clinical Validation of the Six lncRNA Expressions. Overall, six pairs of hepatocellular carcinoma and paracancerous samples were examined to verify the lncRNA expression levels of six genes. The results identified that all six lncRNAs were highly expressed in tumor tissues \((P < 0.001)\) (Figure 5). This was in keeping with the current data analysis.

4. Discussion

TCGA is a comprehensive database containing multiple cancer expression datasets, and the TCGA lncRNA dataset has been widely used in the diagnosis and prognostic prediction of HCC. The prognosis of HCC remains very poor. At present, treatment of liver cancer mainly includes hepatectomy, liver transplantation, radiofrequency ablation, transarterial chemoembolization, and drug treatment. However, these treatments have limited effect, and so far, there is no effective method for accurately predicting the prognostic signatures of patients with liver cancer. Therefore, it is important to determine reliable biomarkers and identify prediction factors for the OS time for patients with HCC.

Accumulating research has indicated that the immune microenvironment has a great effect on the occurrence, progression, response to treatment, and long-term prognosis of patients with liver cancer [26, 27]. Immune cells, as the monitoring cells of the body, can interfere with molecular signals and recognize the abnormal proliferation of tumor cells. These cells have significant roles in the biological function of cancer, containing tumor proliferation, metastasis, and invasion [28]. Moreover, the presence of the immune escape mechanism often affects the prognosis of the tumor. Multiple immunosuppressive cells of the HCC tumor microenvironment participate in the immune escape of tumor cells [29]. Previous research has suggested that the M2 phenotype in TAM produces an inflammatory environment for tumor growth and promotes tumor progression and metastasis by inducing tumor angiogenesis in HCC, which greatly reduces the survival rate of the patients [30]. However, some cancer cells can avoid being detected by the immune system. These can evade the immune system by inhibiting the immune response, such as antigen presentation, thereby promoting tumor invasion [31]. Recent studies have reported that activation of \(\beta\)-catenin promotes immune escape and resistance to programmed cell death 1 (PD-1) and may represent a novel biomarker of T cell rejection in patients with HCC [32]. PD-1, as an immune checkpoint molecule, leads to poor prognosis in patients with cancer by reducing T cell activity and enhancing the immune tolerance of tumor cells. It has also been reported that nivolumab, as an immunosuppressant of PD-1, may play a role in advanced liver cancer [33]. Another study showed that knockout of lncRNA-MM2P could stop the phosphorylation of STAT6, thus preventing the M2 polarization of macrophages by cytokines and weakening the tumor angiogenesis function of M2 macrophages [34].

Previous researchers have systematically and comprehensively studied the function of lncRNAs in HCC. For example, it has been shown that the expression levels of lncRNAs may be dysregulated in HCC, which is closely associated with the occurrence, metastasis, therapeutic target, prognosis, or diagnosis of HCC [13, 35]. Previous studies have reported that the highly expressed lncRNAs HULC [36] and HEIH [37] can promote the development of liver cancer. Accumulating evidence has also suggested IRLs are a potential target for tumor therapy, which has predictive value for prognosis. For instance, a variety of lncRNAs, including lncRNA-D16366, lncRNA-ELMO1-AS1, and lncRNA-AWPPH [38], have been considered as potential therapeutic targets and prognostic signatures for liver cancer. Based on these research results, the present study established a new lncRNA prognosis model. As immune-related

### Table 2: Univariate and multivariate analyses of overall survival in patients with hepatocellular carcinoma from The Cancer Genome Atlas.

| Variables | Univariate analysis | Multivariate analysis |
|-----------|---------------------|-----------------------|
|           | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
| Age (years, increasing years) | 0.995 (0.976-1.014) | 0.603 | 1.003 (0.982-1.024) | 0.801 |
| Sex (female/male) | 0.893 (0.532-1.500) | 0.669 | 1.026 (0.566-1.858) | 0.933 |
| Histologic grade (1/2/3/4) | 1.083 (0.772-1.520) | 0.644 | 1.160 (0.802-1.678) | 0.431 |
| Pathologic stage (1/2/3/4) | 2.084 (1.590-2.733) | 1.07×10⁻⁰⁷ | 1.257 (0.432-3.656) | 0.674 |
| T classification (1/2/3/4) | 1.980 (1.541-2.543) | 8.94×10⁻⁰⁸ | 1.476 (0.555-3.925) | 0.435 |
| M classification (0/1) | 4.769 (1.485-15.311) | 0.009 | 1.779 (0.454-6.966) | 0.408 |
| N classification (0/1) | 2.439 (0.593-10.035) | 0.217 | 2.059 (0.314-13.500) | 0.452 |
| Prognostic model (low/high) | 1.238 (1.163-1.317) | 1.69×10⁻¹¹ | 1.189 (1.109-1.275) | 1.17×10⁻⁰⁶ |

T: tumor; N: node; M: metastasis.
Figure 3: Continued.
Figure 3: Different immune statuses of the low- and high-risk groups in The Cancer Genome Atlas dataset. PCA analysis between the two groups based on (a) immune genes and (b) all genes. (c and d) Gene Set Enrichment Analysis identified a prominent enrichment of immune-associated phenotypes in the high-risk group. The normalized enrichment scores were 1.28 and 1.47, respectively. PC: principal component.
lncRNAs serve an important role in HCC, it is necessary to identify its potential lncRNA biomarkers. Mining of lncRNA datasets in TCGA-LIHC is a reliable method.

In the present study, 341 immune-associated lncRNAs were obtained via coexpression analysis in the TCGA dataset. In the Cox regression analysis of IRLs, 17 lncRNAs were significantly correlated with OS. Then, six immune-related lncRNAs (AC099850.4, NRAV, AL031985.3, PRRT3-as1, AL365203.2, and LINC01224) were identified as prognostic risk factors for HCC. Based on these six IRLs, 329 samples were divided into high- and low-risk groups by calculating the risk values of all samples. The survival analysis suggested

Figure 4: Correlation between the immune-related long noncoding RNA signatures and infiltration abundances of immune cells in The Cancer Genome Atlas dataset. Cor: correlation coefficient.
that the prognosis of the high-risk group was worse ($P = 1.54 \times 10^{-7}$). In addition, all six lncRNAs were risk-related genes (hazard ratio $> 1$), and these lncRNAs were upregulated in the high-risk group. Using multivariate regression analysis, six immune-related lncRNA signatures were identified as independent prognostic factors for HCC. The survival analysis and AUC value of the ROC curve identified that the six prognosis-associated lncRNA model were credible in predicting the overall survival.

In the current study, PCA and GSEA analyses confirmed that high- and low-risk groups were divided into different immune patterns, and high-risk groups were more active with regard to the immune response and process. This result prompts the further investigation of the potential biological mechanism and clinical significance of the prognosis model in future studies.

In order to understand the characteristics of tumor immunity, the present study examined the interaction between the new prognosis model and immune infiltration. The results suggested that the infiltration degree of six types of immune cells may be higher in high-risk patients. Moreover, all six types of immune cells were positively correlated

---

**Figure 5:** Verification of lncRNA expression levels of the six immune prognostic genes. The lncRNA expression levels of AC099850.4, NRAV, AL031985.3, PRRT3-as1, AL365203.2, and LINC01224 in six pairs of hepatocellular carcinoma and adjacent normal tissues were measured using reverse transcription-quantitative PCR. Data were analyzed using a paired $t$-test. ***$P < 0.001$. lncRNA: long noncoding RNA; NRAV: negative regulator of antiviral response; PRRT3-AS1: PRRT3-antisense RNA1; LINC01224: long intergenic nonprotein coding RNA 1224.
with the immune associated lncRNA signatures, suggesting that the signatures may be a prediction factor of incremental immune cell infiltration in the tumor microenvironment. This may provide a novel idea for the immunotherapy of liver cancer.

Current studies have shown that DC infiltration is closely associated with the decline of OS in patients with HCC [39], which is in line with the current results. Previous research has shown that neutrophils promote the growth, development, and resistance to sorafenib of HCC by recruiting macrophages and Treg cells [40]. Previous studies have reported that macrophages promote tumor growth and invasion in HCC and lead to a poor prognosis for liver cancer [41]. At present, it has been revealed that the invasion of B cells in HCC can increase tumor invasiveness and reduce disease-free survival [42]. However, the mechanism involving immune cells in liver cancer progression remains unknown. When investigating the mechanism of immune infiltration in tumor progression, it is expected that novel immunotherapeutic targets for HCC will be identified.

In the present study, six immune-associated lncRNA signatures were identified as potential prognostic biomarkers for liver cancer. The current study used six pairs of HCC tissues and paracancerous tissues to evaluate the lncRNA expression levels of the six genes. The results demonstrated that all six lncRNAs were highly expressed in tumor tissues. Moreover, the experimental results were mostly consistent with those of the TCGA database, which confirmed the reliability of the present model. Recent studies have reported that PRRT3-AS1 may be a potential therapeutic target for GBM [43]. Fan et al. [44] revealed that PRRT3-AS1 was highly expressed in prostate cancer (PC). Furthermore, PRRT3-AS1 silencing is able to activate the peroxisome proliferator-activated receptor γ gene, which can inhibit PC cell proliferation and promote cell apoptosis and autophagy by blocking the mTOR signaling pathway. In addition, Li et al. [45] reported that LINCO1224 may be a potential prognostic marker of breast cancer, while Gong et al. found that LINCO1224 was upregulated in HCC. LINCO1224 silencing can reduce checkpoint kinase 1 expression by competitive binding to miR-330-5p, thereby inhibiting the progression of HCC [46]. Studies have also shown that the downregulation of NRAV is a part of the host’s antiviral defense [47]. However, its role in cancer is yet to be fully clarified.

Based on the current research, the identified lncRNAs may become potential targets for immunotherapy and have great potential for predicting and evaluating the OS of patients with HCC. The advantage of the current study lies in the mining and analysis of TCGA RNA-seq data and the establishment of a novel immune-related prognosis model. This model was powerful in predicting the OS of patients with HCC. Considering the rapid development of immunotherapy for liver cancer in recent years, the present study investigated the relationship between risk score and tumor immune infiltration. However, the disadvantage of the current research was that the model had not been verified by other databases. In the future, the prognostic value of the six-lncRNA signatures will need to be further verified in other independent HCC datasets and larger clinical patients. At the same time, this study lacked the detection of proteomics and immunohistochemistry. Thus, the application value of these immune-related lncRNAs needs to be further clarified in a subsequent study. Despite these limitations, the current research established a novel IRL signature for HCC, which is closely associated with patient risk and OS.

5. Conclusion

In conclusion, this study constructed the coexpression network of immune genes and lncRNAs and identified 341 IRLs. Then, we constructed a prognostic model based on the expression of six prognostic lncRNAs. This model could significantly distinguish the high- and low-risk groups of HCC patients, and the prognosis of patients in the high-risk group was worse. Univariate analysis identified that T classification ($P = 8.94 \times 10^{-8}$), M classification ($P = 0.009$), and the six-lncRNA prognosis model were significantly associated with the OS rate. After the multivariate Cox regression analysis, the prognostic model remained an independent prognostic factor for HCC, which could predict the prognosis better than other traditional clinical indicators. Moreover, the prognostic model was related to the clinical progression of HCC. In addition, the level of immune cell infiltration was higher in the high-risk group. The results would help to establish a reliable risk assessment model and provide new insights into HCC-related immunotherapy strategies.

Abbreviations

GSEA: Gene Set Enrichment Analysis
lncRNA: Long noncoding RNA
IRLS: Immune-related long noncoding RNAs
OS: Overall survival
PCA: Principal component analysis
HCC: Hepatocellular carcinoma
TCGA: The Cancer Genome Atlas.

Data Availability

The datasets used and/or analyzed during the current study are available upon reasonable request from the corresponding author.

Conflicts of Interest

The authors report no conflicts of interest in this work.

Acknowledgments

The present study was supported by the National Natural Science Foundation of China (grant no. 81902983), the Guangxi Natural Science Foundation of China (grant no. 2018JJ140382), “Medical Excellence Award” funded by the creative research development grant from the First Affiliated Hospital of Guangxi Medical University (grant no. 180327), and the Guangxi Medical and Health Technology Development and Application Project (grant nos. S2019097 and S2018100).
Supplementary Materials

Figure S1: differential expression analysis of six long non-coding RNAs in The Cancer Genome Atlas database. Figure S2: survival curves of the six prognostic long noncoding RNAs in hepatocellular carcinoma based on The Cancer Genome Atlas dataset. Figure S3: association between immune-related lncRNAs, risk score, and clinicopathological features in The Cancer Genome Atlas dataset. Table S1: characteristics of the patients with hepatocellular carcinoma in The Cancer Genome Atlas dataset. (Supplementary Materials)

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[2] K. Schulze, J. C. Nault, and A. Villanueva, “Genetic profiling of hepatocellular carcinoma using next-generation sequencing,” Journal of Hepatology, vol. 65, no. 5, pp. 1031–1042, 2016.

[3] J. M. Llovet, A. Villanueva, A. Lachenmayer, and R. S. Finn, “Advances in targeted therapies for hepatocellular carcinoma in the genomic era,” Nature Reviews. Clinical Oncology, vol. 12, no. 7, pp. 408–424, 2015.

[4] S. Colagrande, A. L. Inghilesi, S. Aburas, G. G. Taliani, C. Nardi, and F. Marra, “Challenges of advanced hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 22, no. 34, pp. 7645–7659, 2016.

[5] G. R. Joliat, P. Alleman, I. Labgaa, N. Demartines, and N. Halkic, “Treatment and outcomes of recurrent hepatocellular carcinomas,” Langenbeck’s Archives of Surgery, vol. 402, no. 5, pp. 737–744, 2017.

[6] J. M. Llovet, S. Ricci, V. Mazaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008.

[7] M. Kudo, R. S. Finn, S. Qin et al., “Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial,” Lancet, vol. 391, no. 10126, pp. 1163–1173, 2018.

[8] V. Hernandez-Gea, S. Toffanin, S. L. Friedman, and J. M. Llovet, “Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma,” Gastroenterology, vol. 144, no. 3, pp. 512–527, 2013.

[9] A. Shlomai, Y. P. de Jong, and C. M. Rice, “Viruses associated malignancies: the role of viral hepatitis in hepatocellular carcinoma,” Seminars in Cancer Biology, vol. 26, pp. 78–88, 2014.

[10] D. I. Gabrilovich and S. Nagaraj, “Myeloid-derived suppressor cells as regulators of the immune system,” Nature Reviews. Immunology, vol. 9, no. 3, pp. 162–174, 2009.

[11] M. Liu, J. Zhou, X. Liu et al., “Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma,” Gut, vol. 69, no. 2, pp. 365–379, 2020.

[12] W. K. Mowel, J. J. Kotzin, S. J. McCright, V. D. Neal, and J. Henao-Meja, “Control of immune cell homeostasis and function by lncRNAs,” Trends in Immunology, vol. 39, no. 1, pp. 55–69, 2018.

[13] M. Vitiello, A. Tuccoli, and L. Poliseno, “Long non-coding RNAs in cancer: implications for personalized therapy,” Cellular Oncology (Dordrecht), vol. 38, no. 1, pp. 17–28, 2015.

[14] N. Bartonicek, J. L. Maag, and M. E. Dinger, “Long noncoding RNAs in cancer: mechanisms of action and technological advancements,” Molecular Cancer, vol. 15, no. 1, pp. 1–10, 2016.

[15] R. Jiang, J. Tang, Y. Chen et al., “The long noncoding RNA Inc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion,” Nature Communications, vol. 8, no. 1, article 15129, 2017.

[16] C. J. Wang, C. C. Zhu, J. Xu et al., “The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs,” Molecular Cancer, vol. 18, no. 1, p. 115, 2019.

[17] A. Ally, M. Balasundaram, R. Carlsen et al., “Comprehensive and integrative genomic characterization of hepatocellular carcinoma,” Cell, vol. 169, no. 7, pp. 1327–1341, 2017.

[18] D. A. Barbie, P. Tamayo, J. S. Boehm et al., “Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1,” Nature, vol. 462, no. 7269, pp. 108–112, 2009.

[19] W. Wang, Z. Zhao, F. Yang et al., “An immune-related lncRNA signature for patients with anaplastic gliomas,” Journal of Neuro-Oncology, vol. 136, no. 2, pp. 263–271, 2018.

[20] J. M. Mudge, J. Jungreis, T. Hunt et al., “Discovery of high-confidence human protein-coding genes and exons by whole-genome PhyloCSF helps elucidate 118 GWAS loci,” Genome Research, vol. 29, no. 12, pp. 2073–2087, 2019.

[21] K. H. Zou, K. Tuncali, and S. G. Silverman, “Correlation and simple linear regression,” Radiology, vol. 227, no. 3, pp. 617–628, 2003.

[22] W. Cheng, X. Ren, C. Zhang et al., “Bioinformatic profiling identifies an immune-related risk signature for glioblastoma,” Neurology, vol. 86, no. 24, pp. 2226–2234, 2016.

[23] X. Liau, K. Huang, R. Huang et al., “Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy,” Oncotargets and Therapy, vol. 10, pp. 4493–4506, 2017.

[24] A. Subramanian, P. Tamayo, V. K. Mootha et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15545–15550, 2005.

[25] T. Li, J. Fan, B. Wang et al., “TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells,” Cancer Research, vol. 77, no. 21, pp. e108–e110, 2017.

[26] J. D. Yang, I. Nakamura, and L. R. Roberts, “The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets,” Seminars in Cancer Biology, vol. 21, no. 1, pp. 35–43, 2011.

[27] C. J. Lim, Y. H. Lee, L. Pan et al., “Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma,” Gut, vol. 68, no. 5, pp. 916–927, 2019.

[28] F. Pagés, A. Berger, M. Camus et al., “Effector memory T cells, early metastasis, and survival in colorectal cancer,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2654–2666, 2005.

[29] Y. Wu, D. M. Kuang, W. D. Pan et al., “Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular
carcinoma is mediated by CD48/2B4 interactions,” *Hepatology*, vol. 57, no. 3, pp. 1107–1116, 2013.

[30] B. Z. Qian and J. W. Pollard, “Macrophage diversity enhances tumor progression and metastasis,” *Cell*, vol. 141, no. 1, pp. 39–51, 2010.

[31] Y. Fu, S. Liu, S. Zeng, and H. Shen, “From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma,” *Journal of Experimental & Clinical Cancer Research*, vol. 38, no. 1, p. 396, 2019.

[32] M. Ruiz de Galarreta, E. Bresnahan, P. Molina-Sánchez et al., “β-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma,” *Cancer Discovery*, vol. 9, no. 8, pp. 1124–1141, 2019.

[33] A. B. El-Khoueiry, B. Sangro, T. Yau et al., “Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial,” *Lancet*, vol. 389, no. 10088, pp. 2492–2502, 2017.

[34] J. Cao, R. Dong, L. Jiang et al., “LncRNA-MM2P identified as a modulator of macrophage M2 polarization,” *Cancer Immunology, Immunotherapy*, vol. 7, no. 2, pp. 292–305, 2019.

[35] G. Li, H. Zhang, X. Wan et al., “Long noncoding RNA plays a key role in metastasis and prognosis of hepatocellular carcinoma,” *BioMed Research International*, vol. 2014, Article ID 780521, 8 pages, 2014.

[36] C. H. Li and Y. Chen, “Targeting long non-coding RNAs in cancers: progress and prospects,” *The International Journal of Biochemistry & Cell Biology*, vol. 45, no. 8, pp. 1895–1910, 2013.

[37] Y. He, X. M. Meng, C. Huang et al., “Long noncoding RNAs: novel insights into hepatocellular carcinoma,” *Cancer Letters*, vol. 344, no. 1, pp. 20–27, 2014.

[38] X. Zhao, Y. Liu, and S. Yu, “Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker,” *Biochimica et biophysica acta Molecular basis of disease*, vol. 1863, no. 7, pp. 1805–1816, 2017.

[39] Z. J. Zhou, H. Y. Xin, J. Li, Z. Q. Hu, C. B. Luo, and S. L. Zhou, “Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resection,” *Cancer Immunology, Immunotherapy*, vol. 68, no. 8, pp. 1223–1233, 2019.

[40] S. L. Zhou, Z. J. Zhou, Z. Q. Hu et al., “Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to Sorafenib,” *Gastroenterology*, vol. 150, no. 7, pp. 1646–1658.e17, 2016.

[41] O. W. Yeung, C. M. Lo, C. C. Ling et al., “Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma,” *Journal of Hepatology*, vol. 62, no. 3, pp. 607–616, 2015.

[42] F. Faggioli, E. Palagano, L. Di Tommaso et al., “B lymphocytes limit senescence-driven fibrosis resolution and favor hepatocarcinogenesis in mouse liver injury,” *Hepatology*, vol. 67, no. 5, pp. 1970–1985, 2018.

[43] R. Liang, Y. Zhi, G. Zheng, B. Zhang, H. Zhu, and M. Wang, “Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization,” *OncoTargets and Therapy*, vol. 12, pp. 157–168, 2019.

[44] L. Fan, H. Li, and W. Wang, “Long non-coding RNA PRRT3-AS1 silencing inhibits prostate cancer cell proliferation and promotes apoptosis and autophagy,” *Experimental Physiology*, vol. 105, no. 5, pp. 793–808, 2020.

[45] H. Li, C. Gao, L. Liu et al., “7-lncRNA assessment model for monitoring and prognosis of breast cancer patients: based on cox regression and co-expression analysis,” *Frontiers in Oncology*, vol. 9, p. 1348, 2019.

[46] D. Gong, P. C. Feng, X. F. Ke et al., “Silencing long non-coding RNA LINCO1224 inhibits hepatocellular carcinoma progression via microRNA-330-5p-induced inhibition of CHEK1,” *Mol Ther Nucleic Acids.*, vol. 19, pp. 482–497, 2020.

[47] J. Li, M. Li, X. Wang et al., “Long noncoding RNA NRAV promotes respiratory syncytial virus replication by targeting the microRNA miR-509-3p/Rab5c axis to regulate vesicle transportation,” *Journal of Virology*, vol. 94, no. 10, 2020.